Mankind Pharma has allotted 46,582 equity shares under ESOP on 26 November 2025. With this allotment, the paid up equity share capital has increased to 41,28,05,072 equity shares having face value of Re 1/- each. Powered by Capital Market - Live News

Net profit of Mankind Pharma declined 21.72% to Rs 511.51 crore in the quarter ended September 2025 as against Rs 653.47 crore during the previous quarter ended September 2024. Sales rose 20.77% to Rs 3697.16 crore in the quarter ended September 2025 as against Rs 3061.43 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales3697.163061.43 21 OPM %24.9227.67 - PBDT845.84951.72 -11 PBT624.02851.23 -27 NP511.51653.47 -22 Powered by Capital Market - Live News

Mankind Pharma has received reaffirmation in credit ratings from CRISIL at CRISIL AA+/ Stable / CRISIL A1+. Powered by Capital Market - Live News

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live News

Net profit of Mankind Pharma declined 18.30% to Rs 438.32 crore in the quarter ended June 2025 as against Rs 536.49 crore during the previous quarter ended June 2024. Sales rose 24.50% to Rs 3570.35 crore in the quarter ended June 2025 as against Rs 2867.85 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales3570.352867.85 24 OPM %23.7223.42 - PBDT759.17764.03 -1 PBT540.49661.34 -18 NP438.32536.49 -18 Powered by Capital Market - Live News